Beyond Air, Inc. Share Price & Technical Analysis
XAIR · $0.40 (0.00%)
Healthcare / Medical Devices
$0.40
0.00%
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatm…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-20% return in May, 0% avg return in past 3 year May month.
-46% return in 2026, -135% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 50% | -17% | -22% | -37% | -20% | – | – | – | – | – | – | – | -46% |
| 25 | 3% | -29% | -2% | -28% | -8% | -6% | -12% | -24% | 0% | -9% | -33% | -46% | -193% |
| 24 | -15% | 21% | -15% | -38% | 15% | -59% | 5% | -23% | -9% | 48% | -11% | -30% | -111% |
| 23 | 1% | -8% | 11% | -13% | -9% | -19% | -14% | -16% | -25% | 1% | -32% | 23% | -101% |
| 22 | -28% | 15% | -15% | -12% | -3% | 16% | 38% | 2% | -20% | -10% | -16% | 6% | -27% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.95M
P/E ratio
—
52W high
$5.84
52W low
$0.38
Volume
2,60,503
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Beyond Air, Inc. share price today?
- Beyond Air, Inc. (XAIR) last traded around $0.40 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does XAIR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for XAIR. Download the app for real-time alerts.
- How can I analyze Beyond Air, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.